RHHBY - 3 Best Biotech Stocks to Buy in November
Often, the best investments are the ones most of the market isn't paying attention to. With all eyes focused on coronavirus stocks, it may be a good time for investors to look at the possibilities for progress on other diseases that have plagued us for a lot longer.
Alzheimer's, for example, has proven one of the hardest diseases to treat. At least 400 clinical trials of treatments for it have been conducted over the past 17 years, and not one candidate has shown enough of an impact to earn regulatory approval.
Right now, the number of people across the world with Alzheimer's is estimated to be about 44 million, and that figure is expected to triple by 2050. So as I consider the best biotech stocks to buy in November, I'm focusing on those that are targeting neurological diseases, based on my belief that all of the money pouring into research and development could lead to breakthroughs for companies such as Roche Holdings (OTC: RHHBY) , Cassava Sciences (NASDAQ: SAVA) , and Denali Therapeutics (NASDAQ: DNLI) .
For further details see:
3 Best Biotech Stocks to Buy in November